Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

Intraarterial Therapies Plus Tislelizumab Plus Lenvatinib Versus Tislelizumab Plus Gemcitabine-Cisplatin in Unresectable Intrahepatic Cholangiocarcinoma (RAINBOW)

13 juli 2026 bijgewerkt door: Gao-Jun Teng, Zhejiang Cancer Hospital

Transcatheter Arterial Chemoembolization in Combination With Tislelizumab Plus Lenvatinib Versus Systemic Cisplatin Plus Gemcitabine in Combination With Tislelizumab for Unresectable Intrahepatic Cholangiocarcinoma: A Phase III, Multicenter, Randomized Controlled Trial

This is a phase III, multicenter, open-label, randomized controlled trial designed to evaluate the efficacy and safety of arterially directed therapy in combination with tislelizumab plus lenvatinib compared with gemcitabine and cisplatin (GEMCIS) in combination with tislelizumab as first-line treatment for patients with unresectable intrahepatic cholangiocarcinoma.

Approximately 140 eligible patients with histologically confirmed unresectable intrahepatic cholangiocarcinoma without extrahepatic metastasis will be enrolled and randomized in a 1:1 ratio to receive either TACE plus tislelizumab and lenvatinib or GEMCIS plus tislelizumab. In the TACE-based treatment arm, hepatic arterial infusion chemotherapy with gemcitabine and cisplatin may be administered during or after TACE at the investigator's discretion according to the protocol.

The primary endpoint is overall survival. Secondary endpoints include progression-free survival, time to progression, objective response rate, disease control rate, safety, and quality of life.

Studie Overzicht

Studietype

Ingrijpend

Inschrijving (Geschat)

140

Fase

  • Fase 3

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studiecontact

Studie Contact Back-up

Studie Locaties

    • Guangdong
      • Guangzhou, Guangdong, China, 510060
      • Guangzhou, Guangdong, China, 510317
        • Guangdong Second People's Hospital
        • Contact:
      • Guangzhou, Guangdong, China, 510168
        • Jinshazhou Hospital of Guangzhou University of Chinese Medicine
        • Contact:
      • Guangzhou, Guangdong, China, 511400
        • The Affiliated Panyu Central Hospital of Guangzhou Medical University
        • Contact:
      • Guangzhou, Guangdong, China, 524003
        • The Second Affiliated Hospital of Guangdong Medical University
        • Contact:
      • Jiangmen, Guangdong, China, 529030
        • Jiangmen Central Hospital
        • Contact:
          • Yuchuang Liang
          • Telefoonnummer: +86 13322888181
          • E-mail: jmlyc@21cn.com
    • Hubei
      • Wuhan, Hubei, China, 430022
        • Wuhan Union Hospital of China
        • Contact:
    • Hunan
      • Changsha, Hunan, China, 410013
        • The Third XIANGYA Hospital of Central South University
        • Contact:
      • Changsha, Hunan, China, 410011
        • The Second Xiangya Hospital of Central South University
        • Contact:
    • Jiangxi
      • Ganzhou, Jiangxi, China, 341000
        • Ganzhou Hospital-Nanfang Hospital, Southern Medical University
        • Contact:
      • Nanchang, Jiangxi, China, 330209
        • The First Affiliated Hospital of Nanchang University
        • Contact:
    • Shandong
      • Qingdao, Shandong, China, 266000
        • The Affiliated Hospital of Qingdao University
        • Contact:
    • Sichuan
      • Chengdu, Sichuan, China, 610041
        • West China School of Medicine/West China Hospital, Sichuan University (WCSM/WCH, SCU)
        • Contact:
    • Zhejiang
      • Hangzhou, Zhejiang, China, 310022
        • Zhejiang Cancer Hospital
        • Contact:
        • Contact:
        • Onderonderzoeker:
          • Jiaping Zheng
      • Jinhua, Zhejiang, China, 321000
        • Jinhua Municipal Central Hospital
        • Contact:
      • Lishui, Zhejiang, China, 323020
      • Ningbo, Zhejiang, China, 315010
        • Ningbo No.2 Hospital
        • Contact:
      • Ningbo, Zhejiang, China, 315048
        • Ningbo Medical Center Lihuili Hospital
        • Contact:

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

  • Volwassen
  • Oudere volwassene

Accepteert gezonde vrijwilligers

Nee

Beschrijving

Inclusion Criteria:

  1. Age ≥18 years.
  2. Histologically confirmed intrahepatic cholangiocarcinoma that is unresectable or recurrent after curative treatment, without extrahepatic metastasis.
  3. No prior systemic therapy or transarterial interventional therapy for intrahepatic cholangiocarcinoma.
  4. At least one measurable intrahepatic lesion according to RECIST v1.1.
  5. ECOG performance status of 0 or 1.
  6. Child-Pugh class A liver function.
  7. Life expectancy ≥3 months.
  8. Adequate hematologic, hepatic, renal, and thyroid function within 14 days before study start, defined as:

    • Absolute neutrophil count ≥1.5 × 10⁹/L;
    • Platelet count ≥75 × 10⁹/L;
    • Hemoglobin ≥90 g/L;
    • Serum albumin ≥30 g/L;
    • Total bilirubin ≤1.5 × upper limit of normal;
    • AST and ALT <1.5 × upper limit of normal, and ALP <4 × upper limit of normal;
    • TSH <1 × upper limit of normal, with T3 and T4 within the normal range;
    • Serum creatinine <1.5 × upper limit of normal and creatinine clearance ≥60 mL/min.

Exclusion Criteria:

  1. Diffuse infiltrative liver lesions.
  2. Contraindications to TACE.
  3. Allergy to intravenous contrast agent.
  4. pregnant or breastfeeding women, or participants planning pregnancy within 2 years / unwilling to use effective contraception.
  5. Patients with HIV or syphilis infection.
  6. Patients with concurrent malignancies or other malignancies within 5 years before enrollment.
  7. History of allogeneic organ transplantation.
  8. Severe dysfunction of the heart, kidney, or other organs.
  9. Severe clinically active infection > grade 2 according to NCI-CTC v5.0.
  10. Psychiatric illness that may affect the informed consent process; Inability to take oral medications; Participation in another drug clinical trial within 12 months before enrollment.

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Primair doel: Behandeling
  • Toewijzing: Gerandomiseerd
  • Interventioneel model: Parallelle opdracht
  • Masker: Geen (open label)

Wapens en interventies

Deelnemersgroep / Arm
Interventie / Behandeling
Experimenteel: TACE Plus Tislelizumab and Lenvatinib
Participants will receive tislelizumab 200 mg intravenously every 3 weeks and oral lenvatinib once daily at a starting dose of 12 mg for body weight ≥60 kg or 8 mg for body weight <60 kg. TACE will be performed after initiation of lenvatinib and may be repeated based on radiologic response, residual viable tumor, liver function, and investigator assessment. Both conventional TACE (cTACE) and drug-eluting beads TACE are allowed, and hepatic artery infusion chemotherapy may be added at investigator's discretion. Treatment will continue until clinical progression, radiologic progressive disease according to RECIST v1.1, completion of 2 years of immunotherapy, unacceptable toxicity, withdrawal of consent, or other discontinuation criteria.
Tislelizumab 200 mg intravenously on Day 1 of each 21-day cycle, followed by maintenance tislelizumab every 3 weeks.
Oral lenvatinib once daily, 12 mg for participants with body weight ≥60 kg or 8 mg for participants with body weight <60 kg, with dose modification according to toxicity.
Conventional TACE or drug-eluting bead TACE are allowed. TACE may be repeated based on imaging assessment every 6 weeks ±7 days and investigator judgment.
Optional hepatic arterial infusion chemotherapy with gemcitabine and cisplatin may be administered during or after TACE at the investigator's discretion according to protocol-defined dose ranges.
Actieve vergelijker: Gemcitabine-Cisplatin Plus Tislelizumab
Participants will receive cisplatin 25 mg/m² on Day 1 and Day 8, gemcitabine 1000 mg/m² on Days 1 and 8, and tislelizumab 200 mg on Day 1 of each 3-week cycle for up to 8 cycles. After completion of gemcitabine-cisplatin treatment, participants will continue tislelizumab 200 mg intravenously every 3 weeks. Treatment will continue until clinical progression, radiologic progressive disease according to RECIST v1.1, completion of 2 years of immunotherapy, unacceptable toxicity, withdrawal of consent, or other discontinuation criteria.
Tislelizumab 200 mg intravenously on Day 1 of each 21-day cycle, followed by maintenance tislelizumab every 3 weeks.
Gemcitabine 1000 mg/m² intravenously on Days 1 and 8 of each 21-day cycle, up to 8 cycles.
Cisplatin 25 mg/m² intravenously on Day 1 and Day 8 of each 21-day cycle, up to 8 cycles.

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Overall Survival
Tijdsspanne: From randomization to death from any cause, assessed up to approximately 48 months
Overall survival is defined as the time from enrollment/randomization to death from any cause. Participants who withdraw are lost to follow-up or remain alive at the end of the study will be censored at the date they were last known to be alive.
From randomization to death from any cause, assessed up to approximately 48 months

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Progression-Free Survival
Tijdsspanne: From randomization to disease progression or death, assessed up to approximately 48 months
Defined as the time from randomization to disease progression or death from any cause. Participants without progression or death will be censored at the last date known to be progression-free.
From randomization to disease progression or death, assessed up to approximately 48 months
Time to Progression
Tijdsspanne: From randomization to disease progression, assessed up to approximately 48 months
Defined as the time from randomization to disease progression. Participants who die without prior progression, withdraw, are lost to follow-up, or remain progression-free at study end will be censored at the last date known to be progression-free.
From randomization to disease progression, assessed up to approximately 48 months
Objective Response Rate
Tijdsspanne: Assessed every 6 weeks ±7 days, up to approximately 48 months
Defined as the proportion of participants achieving complete response or partial response according to RECIST v1.1.
Assessed every 6 weeks ±7 days, up to approximately 48 months
Disease Control Rate
Tijdsspanne: Assessed every 6 weeks ±7 days, up to approximately 48 months
Defined as the proportion of participants achieving complete response, partial response, or stable disease according to RECIST v1.1.
Assessed every 6 weeks ±7 days, up to approximately 48 months
Incidence of Grade ≥3 Adverse Events
Tijdsspanne: From first dose of study treatment through 28 days after the last dose of study treatment
Defined as the occurrence of grade 3 or higher hematologic or non-hematologic toxicities, graded according to CTCAE v5.0.
From first dose of study treatment through 28 days after the last dose of study treatment
Quality of Life Assessed by the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30)
Tijdsspanne: Baseline and during treatment/follow-up, assessed up to approximately 48 months
The European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 is a 30-item questionnaire used to assess health-related quality of life in patients with cancer. Scores are linearly transformed to a 0 to 100 scale. For the global health status/quality-of-life scale and functional scales, higher scores indicate better health-related quality of life or functioning. For symptom scales and single symptom items, higher scores indicate a higher symptom burden or worse symptoms.
Baseline and during treatment/follow-up, assessed up to approximately 48 months
Quality of Life Assessed by the EuroQol Five-Dimension (EQ-5D)
Tijdsspanne: Baseline and during treatment/follow-up, assessed up to approximately 48 months
The EuroQol Five-Dimension Three-Level Questionnaire is a standardized instrument for measuring health-related quality of life. The descriptive system includes five dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension is scored from 1 to 3, where 1 indicates no problems, 2 indicates some or moderate problems, and 3 indicates extreme problems or inability to perform the activity. Higher scores in each dimension indicate more severe problems or worse health status.
Baseline and during treatment/follow-up, assessed up to approximately 48 months

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Onderzoekers

  • Hoofdonderzoeker: Gaojun Teng, MD, Zhejiang Cancer Hospital
  • Hoofdonderzoeker: Min Kuang, MD, First Affiliated Hospital, Sun Yat-Sen University
  • Hoofdonderzoeker: Jiansong Ji, MD, The Central Hospital of Lishui City

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Geschat)

1 juli 2026

Primaire voltooiing (Geschat)

1 januari 2030

Studie voltooiing (Geschat)

1 juli 2030

Studieregistratiedata

Eerst ingediend

30 juni 2026

Eerst ingediend dat voldeed aan de QC-criteria

30 juni 2026

Eerst geplaatst (Werkelijk)

9 juli 2026

Updates van studierecords

Laatste update geplaatst (Werkelijk)

14 juli 2026

Laatste update ingediend die voldeed aan QC-criteria

13 juli 2026

Laatst geverifieerd

1 juli 2026

Meer informatie

Termen gerelateerd aan deze studie

Plan Individuele Deelnemersgegevens (IPD)

Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?

NEE

Beschrijving IPD-plan

Individual participant data will not be shared due to privacy, ethical, and regulatory considerations.

Informatie over medicijnen en apparaten, studiedocumenten

Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel

Nee

Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct

Nee

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren